Shares of GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) traded up 0.4% during trading on Monday . The company traded as high as $20.85 and last traded at $20.67. 1,298,200 shares were traded during trading, an increase of 2,574% from the average session volume of 48,553 shares. The stock had previously closed at $20.59.
GENMAB A/S/S Trading Down 0.8 %
The stock’s fifty day simple moving average is $23.59 and its 200 day simple moving average is $26.08.
About GENMAB A/S/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Read More
- Five stocks we like better than GENMAB A/S/S
- Why Are These Companies Considered Blue Chips?
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- How to Use the MarketBeat Stock Screener
- Williams-Sonoma Stock: Buy It and Never Let It Go
- What Investors Need to Know to Beat the Market
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png?v=20230608083651&h=45&w=95&zc=2){kind=logo}
